Do Companies Implementing Decentralized Trials Have Sufficient Regulatory Guidance?

Source: Clinical Leader

In 2020 the industry saw a surge in the adoption of decentralized clinical trials. The model allowed drug developers to continue their studies while keeping patients safe and out of clinics. As the COVID-19 pandemic winds down, most researchers expect the decentralized model to be the new norm going forward. Still, there are challenges that will need to be overcome for this new model to succeed. A research report published by Oracle Health Sciences has identified several of those challenges that still exist.

In this webinar segment, Tero Laulajainen, VP and head of global clinical science and operations for UCB, and Hassan Kadhim, global head of clinical trial business capabilities, clinical innovation, and industry collaborations at Bristol-Myers Squibb discuss the guidance issued by regulators to help drug developers that are implementing decentralized trials.

access the Video!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Clinical Leader